(NASDAQ: NKTR) Nektar Therapeutics's forecast annual revenue growth rate of -11.16% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Nektar Therapeutics's revenue in 2024 is $90,167,000.On average, 5 Wall Street analysts forecast NKTR's revenue for 2024 to be $13,542,315,725, with the lowest NKTR revenue forecast at $6,922,648,174, and the highest NKTR revenue forecast at $15,687,051,287. On average, 5 Wall Street analysts forecast NKTR's revenue for 2025 to be $11,697,990,042, with the lowest NKTR revenue forecast at $4,205,003,798, and the highest NKTR revenue forecast at $15,248,188,445.
In 2026, NKTR is forecast to generate $11,962,409,495 in revenue, with the lowest revenue forecast at $4,333,541,032 and the highest revenue forecast at $17,941,961,620.